First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
Diagnosis & Disease Information
No Survival Benefit With Nivolumab Plus Ipilimumab in R/M Head and Neck Squamous Cell Carcinoma
The phase 3 CheckMate 651 trial showed prolonged overall survival and durable responses in specific subsets of patients.
Cancer Patients With COVID-19 Less Likely to Receive Critical Care Despite Higher Risk of Death
Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.
Avelumab Doesn’t Improve Upon Standard Care for Head and Neck Cancer
Avelumab plus cetuximab and radiotherapy did not improve progression-free survival over standard care in cisplatin-fit or -unfit patients.
Pembrolizumab Monotherapy Promising for MSI-H Advanced Endometrial Cancer
The duration of response was more than 3 years in 68% of patients.
Tumor Microenvironment Cellular Makeup May Predict Nivolumab Response for Patients With Hodgkin Lymphoma
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
R-NPLD Combination Treatment Safe and Effective for Patients With Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.
Factors Tied to COVID-19 Severity, Recovery, and Death in Cancer Patients
Non-Caucasian patients had a greater risk of developing severe COVID-19, but Asian patients had a lower risk of death from COVID-19.
COVID-19 Prognosis Improved Over Time for Cancer Patients
Compared with patients who had COVID-19 during the second outbreak, patients diagnosed during the first outbreak had an increased risk of death at 14 days and at 3 months.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
- Loading...
Loading...
Loading... 
Loading...